Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Omega Diagnostic (LON: ODX) said on Friday that its technology partner, Mologic, has filed its submission to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its Covid-19 antigen test.
The test will be used under Omega's VISITECT and Global Access Diagnostics (GAD) brands.
Colin King, CEO of Omega, commented: “We are very pleased that the regulatory process to make our VISITECT COVID-19 Antigen test available in the US professional use is progressing well. We believe we have a high-quality, high-performance product with significant global appeal and the US market, due to both its size and high barriers to entry, would be a very attractive commercial market for our product.”
At the beginning of June, the company revealed it was in the process of seeking CE marking for the rapid point-of-care antigen test to be sold for home use in Europe by late July.
Omega Diagnostics share price is currently up 3.43% at 55.85p, below the 59p highs seen earlier in Friday's session.
Omega Diagnostics shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Omega shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .